Gentex Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Gentex (GNTX)
Gentex lowered its 2026 revenue guidance to approximately $2.65 billion, down from a prior range of $2.65 billion to $2.75 billion. Shareholders holding losses may have rights wort...
Earnings call transcript: Gentex misses Q3 2026 estimates, shares fall 6.8%
Glaukos (GKOS) Q3 2026 Earnings Call Transcript
Record sales and margin expansion driven by iDose TR and Epioxa launches.
SpyGlass Pharma reports 4-year glaucoma implant trial results
Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - Slideshow
MeiraGTx chief scientific officer Naylor sells $294,291 in shares
Meet the Super Semiconductor Stock Crushing Nvidia in 2026
This 175-year-old glassmaker is now at the center of the artificial intelligence boom.
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation...
GNT And GNT.PR.A: Balancing Yield, Security, And Interest Rate Risk
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Q3 2026 Earnings Call Transcript
Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow
<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…
Cognex Corporation 2026 Q3 - Results - Earnings Call Presentation
Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript
PT GoTo Gojek Tokopedia Tbk (GTOFF) Q3 2026 Earnings Call Transcript
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow
Vuzix: Promising IP Within Data Centers And Industrial Settings, But Too Risky
ER-100 – aging reversal drug first test results in the EYE with Glaucoma announced
Safety phase. 2 of 3 patients given LOW DOSES reported vision improvement. Phase 2 – Doses will now triple in size for next round. Today, at the American Academy of Ophthalmology A...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.